Yasuhiro Miki

List of Publications by Year
in descending order

109 papers	3,452 citations	126907 33 h-index	155660 55 g-index
110 all docs	110 docs citations	110 times ranked	4226 citing authors

#	Article	IF	Citations
1	Intratumoral Estrogens and Estrogen Receptors in Human Nonâ€“Small Cell Lung Carcinoma. Clinical Cancer Research, 2008, 14, 4417-4426.	7.0	179
2	Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5760-5768.	3.6	156
3	Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer, 2005, 12, 701-720.	3.1	156
4	Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research, 2003, 63, 2762-70.	0.9	146
5	The advantages of co-culture over mono cell culture in simulating in vivo environment. Journal of Steroid Biochemistry and Molecular Biology, 2012, 131, 68-75.	2.5	143
6	Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Molecular and Cellular Endocrinology, 2005, 231, 75-85.	3.2	133
7	Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Research, 2006, 66, 535-542.	0.9	132
8	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells. Cancer Research, 2007, 67, 3945-3954.	0.9	117
9	In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. Pathology International, 2009, 59, 777-789.	1.3	80
10	Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Research, 2005, 65, 657-63.	0.9	75
11	Intracrinology of estrogens and androgens in breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 181-185.	2.5	73
12	5Î±-Reductase type 1 and aromatase in breast carcinoma as regulators ofin situ androgen production. International Journal of Cancer, 2007, 120, 285-291.	5.1	71
13	Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. Cancer Science, 2013, 104, 639-646.	3.9	71
14	Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer, 2008, 15, 113-124.	3.1	70
15	Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Science, 2010, 101, 2670-2675.	3.9	68
16	Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocrine-Related Cancer, 2010, 17, 415-430.	3.1	64
17	Sex steroid receptors in rheumatoid arthritis. Clinical Science, 2004, 106, 293-300.	4.3	59
18	Hexokinase <scp>II</scp> in breast carcinoma: A potent prognostic factor associated with hypoxiaâ€inducible factorâ€1Î± and <scp>K</scp>iâ€67. Cancer Science, 2013, 104, 1380-1388.	3.9	59

#	Article	IF	Citations
19	Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors. Cancer Research, 2009, 69, 914-922.	0.9	56
20	NRF2 immunolocalization in human breast cancer patients as a prognostic factor. Endocrine-Related Cancer, 2014, 21, 241-252.	3.1	55
21	Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: Possible regulator of in situ steroidogenesis. Cancer Letters, 2006, 244, 24-33.	7.2	52
22	PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells. Cancers, 2019, 11, 1257.	3.7	52
23	Intratumoral Localization of Aromatase and Interaction between Stromal and Parenchymal Cells in the Nonâ€“Small Cell Lung Carcinoma Microenvironment. Cancer Research, 2010, 70, 6659-6669.	0.9	49
24	Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. Bone, 2007, 40, 876-887.	2.9	46
25	Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 2013, 142, 211-223.	2.5	45
26	Sex steroid receptors expression and hormoneâ€induced cell proliferation in human osteosarcoma. Cancer Science, 2008, 99, 518-523.	3.9	44
27	An activation of <scp>LC3A</scp>â€mediated autophagy contributes to de novo and acquired resistance to <scp>EGFR</scp> tyrosine kinase inhibitors in lung adenocarcinoma. Journal of Pathology, 2014, 234, 277-288.	4.5	44
28	Steroid Sulfatase and Estrogen Sulfotransferase in the Atherosclerotic Human Aorta. American Journal of Pathology, 2003, 163, 1329-1339.	3.8	40
29	Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Research and Treatment, 2009, 116, 371-378.	2.5	38
30	17Î²-Hydroxysteroid Dehydrogenase Type 12 in Human Breast Carcinoma: A Prognostic Factor via Potential Regulation of Fatty Acid Synthesis. Cancer Research, 2009, 69, 1392-1399.	0.9	36
31	Androgens in human breast carcinoma. Medical Molecular Morphology, 2010, 43, 75-81.	1.0	36
32	Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Molecular and Cellular Endocrinology, 2011, 340, 148-153.	3.2	36
33	In situ production of sex steroids in human breast carcinoma. Medical Molecular Morphology, 2007, 40, 121-127.	1.0	34
34	S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells. Cellular Oncology (Dordrecht), 2019, 42, 67-80.	4.4	33
35	Aromatase in Human Breast Carcinoma as a Key Regulator of Intratumoral Sex Steroid Concentrations. Endocrine Journal, 2008, 55, 455-463.	1.6	32
36	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. Journal of Translational Medicine, 2012, 10, S2.	4.4	32

#	Article	IF	Citations
37	Aryl Hydrocarbon Receptor in Breast Cancerâ€"A Newly Defined Prognostic Marker. Hormones and Cancer, 2014, 5, 11-21.	4.9	32
38	The role of 5Î±-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. Molecular and Cellular Endocrinology, 2015, 401, 56-64.	3.2	32
39	Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Research and Treatment, 2016, 155, 65-75.	2.5	30
40	Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer, 2008, 15, 270-277.	2.9	28
41	Controversies of aromatase localization in human breast cancerâ€"Stromal versus parenchymal cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 97-101.	2.5	27
42	Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: Estrogen receptor dependent or independent pathways of raloxifene. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 281-289.	2.5	26
43	The role of estrogen-metabolizing enzymes and estrogen receptors in human epidermis. Molecular and Cellular Endocrinology, 2011, 344, 35-40.	3.2	26
44	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. Endocrine-Related Cancer, 2016, 23, R323-R335.	3.1	24
45	Immunolocalization of estrogenâ€producing and metabolizing enzymes in benign breast disease: Comparison with normal breast and breast carcinoma. Cancer Science, 2010, 101, 2286-2292.	3.9	23
46	Local Biosynthesis of Estrogen in Human Endometrial Carcinoma through Tumor-Stromal Cell Interactions. Clinical Cancer Research, 2009, 15, 6028-6034.	7.0	22
47	In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 159-169.	2.5	22
48	The Significance of MMP-1 in EGFR-TKIâ€"Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. International Journal of Molecular Sciences, 2018, 19, 609.	4.1	21
49	Impact of COVID-19 restrictions on the research environment and motivation of researchers in Japan. Progress in Disaster Science, 2020, 8, 100128.	2.7	21
50	Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: Comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 68-71.	2.5	19
51	Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: A potent prognostic factor. Cancer Science, 2010, 101, 543-549.	3.9	19
52	Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. International Journal of Molecular Sciences, 2017, 18, 2159.	4.1	19
53	Exploring Proteinâ€"Protein Interaction in the Study of Hormone-Dependent Cancers. International Journal of Molecular Sciences, 2018, 19, 3173.	4.1	19
54	Assessment of protein expression and gene status of human epidermal growth factor receptor (<scp>HER</scp>) family molecules in ameloblastomas. Journal of Oral Pathology and Medicine, 2013, 42, 424-434.	2.7	18

#	Article	IF	Citations
55	Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the Î²-Catenin Pathway in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 2438.	4.1	18
56	Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sciences, 2016, 155, 29-35.	4.3	17
57	The significance of lipid accumulation in breast carcinoma cells through perilipin 2 and its clinicopathological significance. Pathology International, 2019, 69, 463-471.	1.3	17
58	Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Research and Treatment, 2017, 161, 399-407.	2.5	16
59	Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma. Human Pathology, 2018, 77, 88-97.	2.0	16
60	ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. International Journal of Molecular Sciences, 2018, 19, 804.	4.1	16
61	Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells. International Journal of Molecular Sciences, 2021, 22, 1918.	4.1	16
62	Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling. Breast Cancer Research and Treatment, 2020, 180, 97-110.	2.5	16
63	Immunohistochemical assessment of growth factor signaling molecules: MAPK, Akt, and STAT3 pathways in oral epithelial precursor lesions and squamous cell carcinoma. Odontology / the Society of the Nippon Dental University, 2020, 108, 91-101.	1.9	14
64	Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma. Breast Cancer Research and Treatment, 2017, 166, 709-723.	2.5	13
65	<i>In Situ</i> Evaluation of Estrogen Receptor Dimers in Breast Carcinoma Cells: Visualization of Protein-Protein Interactions. Acta Histochemica Et Cytochemica, 2017, 50, 85-93.	1.6	13
66	17Î²-Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 1139.	4.1	13
67	Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. Breast Cancer, 2020, 27, 919-928.	2.9	13
68	Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Human Pathology, 2013, 44, 2338-2345.	2.0	12
69	Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. Molecular and Cellular Endocrinology, 2014, 392, 136-143.	3.2	12
70	Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells. Clinical and Experimental Metastasis, 2019, 36, 423-432.	3.3	11
71	Suppression of tumor immune microenvironment via microRNAâ€1 after epidermal growth factor receptorâ€tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Medicine, 2021, 10, 718-727.	2.8	11
72	Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive MÃ¼llerian duct cells using microarray. Cancer Letters, 2005, 220, 197-210.	7.2	10

#	Article	IF	Citations
73	The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma. Molecular and Cellular Endocrinology, 2018, 466, 31-37.	3.2	10
74	Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. Breast Cancer, 2021, 28, 915-926.	2.9	10
75	Analysis for Localization of Steroid Sulfatase in Human Tissues. Methods in Enzymology, 2005, 400, 303-316.	1.0	9
76	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Science, 2014, 105, 1503-1509.	3.9	9
77	Prognostic significance of combining immunohistochemical markers for cancer-associated fibroblasts in lung adenocarcinoma tissue. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 181-189.	2.8	9
78	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. Breast Cancer Research and Treatment, 2016, 156, 45-55.	2.5	8
79	Amyloid precursor protein and its phosphorylated form in non-small cell lung carcinoma. Pathology Research and Practice, 2019, 215, 152463.	2.3	8
80	Cervical cancer screening rates before and after the Great East Japan Earthquake in the Miyagi Prefecture, Japan. PLoS ONE, 2020, 15, e0229924.	2.5	8
81	New Insights into Breast and Endometrial Cancers. Cancers, 2020, 12, 2595.	3.7	7
82	EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 8522.	4.1	7
83	Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor Î± in endometrial cancer. Pathology Research and Practice, 2022, 231, 153795.	2.3	7
84	11Î² hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. British Journal of Cancer, 2020, 123, 61-71.	6.4	6
85	Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 2581.	4.1	6
86	Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. Pathology International, 2013, 63, 20-28.	1.3	5
87	The interaction between carcinoembryonic antigenâ€related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer. Journal of Pathology, 2018, 246, 379-389.	4.5	5
88	B7â€1 and programmed cell deathâ€ligand 1 in primary and lymph node metastasis lesions of nonâ€small cell lung carcinoma. Cancer Medicine, 2022, 11, 479-491.	2.8	5
89	Aromatase in normal and diseased liver. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.7	4
90	Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. Histology and Histopathology, 2019, 34, 1365-1375.	0.7	4

#	Article	IF	Citations
91	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochemica Et Cytochemica, 2022, 55, 25-35.	1.6	4
92	Appropriate Health Management Considering the Vulnerability of Women during Disasters. Tohoku Journal of Experimental Medicine, 2022, 256, 187-195.	1.2	4
93	Analysis of multiple primary cancer autopsy cases associated with breast cancer: 2002â€“2010. Pathology International, 2016, 66, 695-700.	1.3	3
94	Androgens enhance the ability of intratumoral macrophages to promote breast cancer progression. Oncology Reports, 2021, 46, .	2.6	3
95	Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors. Pathology Research and Practice, 2022, 230, 153758.	2.3	3
96	FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer. Pathology Research and Practice, 2022, 234, 153898.	2.3	3
97	D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. Histology and Histopathology, 2021, , 18362.	0.7	3
98	Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis. Human Pathology, 2018, 81, 121-130.	2.0	2
99	Multiple primary cancers associated with endometrial and ovarian cancers: An analysis based upon the Japan Autopsy Annual Database from 2002 to 2010. Journal of Obstetrics and Gynaecology Research, 2019, 45, 1012-1018.	1.3	2
100	Vasohibinâ€1 and miRâ€720 expression in diffuse pulmonary capillary hemangiomatosisâ€like changes associated with pulmonary hypoplasia. Pathology International, 2020, 70, 470-472.	1.3	2
101	The Visualization of Protein-Protein Interactions in Breast Cancer: Deployment Study in Pathological Examination. Acta Histochemica Et Cytochemica, 2021, 54, 177-183.	1.6	2
102	New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors. Expert Review of Endocrinology and Metabolism, 2007, 2, 367-374.	2.4	0
103	Microtubule-Associated Protein 2 as a DHEA Binding Protein in Endometrial Cancer. Journal of the Endocrine Society, 2021, 5, A1026-A1027.	0.2	0
104	Title is missing!. , 2020, 15, e0229924.		0
105	Title is missing!. , 2020, 15, e0229924.		0
106	Title is missing!. , 2020, 15, e0229924.		0
107	Title is missing!. , 2020, 15, e0229924.		0
108	Title is missing!. , 2020, 15, e0229924.		0

#	Article	IF	Citations
109	Title is missing!. , 2020, 15, e0229924.		0